Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosedAgreement • February 3rd, 2023 • Polyrizon Ltd. • Pharmaceutical preparations
Contract Type FiledFebruary 3rd, 2023 Company IndustryThis Agreement (the “Agreement”) is made and entered into this 7th day of June 2022 (“Effective Date”) by and between Polyrizon Ltd., Company Number 513637025 located at 5 Hatidhar St. R’annana, Israel. (“Polyrizon”), and NurExone Biologic Ltd., Company No. 516209202 located at 9 Mezada St., Bney Brak, Israel (“Nurexone”). (collectively referred to as “Parties” and each may be referred individually as a “Party”).
Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosedAgreement • October 7th, 2022 • Polyrizon Ltd. • Pharmaceutical preparations
Contract Type FiledOctober 7th, 2022 Company IndustryThis Agreement (the “Agreement”) is made and entered into this 7th day of June 2022 (“Effective Date”) by and between Polyrizon Ltd., Company Number 513637025 located at 5 Hatidhar St. R’annana, Israel. (“Polyrizon”), and NurExone Biologic Ltd., Company No. 516209202 located at 9 Mezada St., Bney Brak, Israel (“Nurexone”). (collectively referred to as “Parties” and each may be referred individually as a “Party”).